Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for Protalix BioTherapeutics in a report released on Friday, May 23rd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of $0.09 for the quarter. HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics' Q2 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.12 EPS and Q4 2026 earnings at $0.14 EPS.
Separately, Wall Street Zen lowered shares of Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 12th.
Get Our Latest Research Report on PLX
Protalix BioTherapeutics Price Performance
NYSE PLX traded down $0.06 during trading on Monday, hitting $1.54. The company's stock had a trading volume of 165,992 shares, compared to its average volume of 543,371. The company has a market cap of $122.20 million, a PE ratio of -11.81 and a beta of -0.05. The business's 50 day simple moving average is $2.34 and its 200-day simple moving average is $2.19. Protalix BioTherapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $3.10.
Protalix BioTherapeutics (NYSE:PLX - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.05) earnings per share for the quarter. Protalix BioTherapeutics had a negative return on equity of 30.89% and a negative net margin of 21.03%.
Institutional Investors Weigh In On Protalix BioTherapeutics
Institutional investors and hedge funds have recently made changes to their positions in the stock. Y Intercept Hong Kong Ltd acquired a new position in shares of Protalix BioTherapeutics in the 4th quarter valued at $35,000. Northern Trust Corp grew its stake in Protalix BioTherapeutics by 1,299.4% during the 4th quarter. Northern Trust Corp now owns 731,742 shares of the company's stock valued at $1,376,000 after purchasing an additional 679,451 shares during the last quarter. Marshall Wace LLP purchased a new stake in Protalix BioTherapeutics during the 4th quarter valued at about $192,000. Renaissance Technologies LLC increased its holdings in shares of Protalix BioTherapeutics by 17.0% in the fourth quarter. Renaissance Technologies LLC now owns 1,118,000 shares of the company's stock valued at $2,102,000 after purchasing an additional 162,100 shares during the period. Finally, PFG Investments LLC purchased a new position in shares of Protalix BioTherapeutics in the fourth quarter worth about $39,000. 16.53% of the stock is currently owned by institutional investors and hedge funds.
About Protalix BioTherapeutics
(
Get Free Report)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
Read More
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
